How can traceability and supply-chain regulation curb the threat of falsified and diverted medicines in India? Suggest measures.
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →WHO estimates that at least 1 in 10 medical products in low- and middle-income countries is substandard or falsified, and that countries spend about US$30.5 billion a year on them [2]. India's regulation has focused on the factory. The Health Ministry's proposal to add Good Storage and Distribution Practices (GSDP) to the Drugs Rules, 1945 [1] now targets the gap between the factory and the patient, where fake drugs get in and genuine stock leaks out of authorised channels.
How traceability and supply-chain regulation help
- Closing entry points: GSDP covers procurement, storage, transport and record-keeping by manufacturers, importers, wholesalers and stockists. It names falsification and diversion as specific risks [1].
- Following a product: QR codes or barcodes are already required on the top 300 brands and on bulk APIs [3]. Batch-level records let regulators trace a suspect pack back to where it came from.
- Placing blame correctly: A Parliamentary Committee put NSQ (Not of Standard Quality) drugs at 7–8% [4]. Today's recalls target the manufacturer [3]. Temperature and movement logs can show whether a drug was badly made or spoiled later in storage.
- Moving guidance into law: Turning CDSCO's guidance into Rules makes compliance enforceable by Central and State drug controllers [1].
- Meeting the global standard: Aligning with WHO TRS 1025, Annex 7 [5] helps the credibility of Indian exports.
Gaps that limit impact
- The Mashelkar Committee found too few trained staff and uneven enforcement across States [4].
- Risk-based inspection has so far covered manufacturing units, with 905 inspected [3], not warehouses.
- Online sellers are a growing route for falsified drugs [2], but the proposal does not name them [1].
Measures
- Track-and-trace for every pack: extend QR codes beyond the top brands and link them to a national verification database.
- Workload-based inspector posts in the States, as Mashelkar recommended [4].
- Sampling at the distribution stage, from stockists and wholesalers, not just factories.
- Phased compliance for small stockists, starting with a self-check tool like WHO's GSDP Warehouse Rapid Assessment Tool [6].
- Clearly cover e-pharmacies and couriers in the final notification.
- Public verification: let patients scan and report suspect packs.
Traceability changes drug regulation from catching problems after the fact to preventing them. If GSDP is backed by enough inspectors, digital tracking and clear coverage, it can protect every medicine on its way to the patient. That supports the right to health under Article 21 and SDG 3.8 (access to safe, quality medicines).
Sources
- 1PIB: Union Ministry of Health Proposes Incorporation of Good Storage and Distribution Practices into Drugs Rules, 1945 (Nov 2026)GSDP scope, entities covered, falsification and diversion risks, guidance becoming enforceable Rules, Central–State enforcement
- 2WHO Fact Sheet: Substandard and falsified medical products1 in 10 estimate, US$30.5 billion spent, online sales as a route
- 3PIB: Steps taken to Prevent Sale of Adulterated DrugsQR codes on top-300 brands and APIs, 905 units inspected, drug alerts and manufacturer recalls
- 4PRS: Demand for Grants 2018-19 Analysis, Health and Family WelfareNSQ estimate of 7–8%, Mashelkar Committee findings on staffing and inspector workload
- 5WHO TRS 1025, Annex 7: Good storage and distribution practices for medical productsthe global GSDP benchmark
- 6WHO eManual: GSDP Warehouse Rapid Assessment Toolwarehouse self-assessment tool